SCHEMBL12298074

SCHEMBL12298074

CCN(CC)c1ccc(-c2csc(Nc3cc(Cl)cc(Cl)c3)n2)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALOX5 P09917 7/20 0.70
▸ MEN1 O00255 3/20 0.58
▸ KMT2A Q03164 3/20 0.58
▸ NPC1 O15118 2/20 0.58
▸ RAB9A P51151 2/20 0.58
▸ GAA P10253 1/20 0.58
▸ CASP3 P42574 1/20 0.58
▸ SENP8 Q96LD8 1/20 0.58
▸ SENP7 Q9BQF6 1/20 0.58
▸ SENP6 Q9GZR1 1/20 0.58
▸ CYP1A1 P04798 5/20 0.58
▸ CYP1A2 P05177 5/20 0.58
▸ CYP1B1 Q16678 5/20 0.58
▸ VCP P55072 2/20 0.50
▸ MAPT P10636 2/20 0.50
▸ ALOX15 P16050 2/20 0.50
▸ ALDH1A1 P00352 1/20 0.50
▸ LMNA P02545 1/20 0.50
▸ ALOX12 P18054 1/20 0.50
▸ HSD17B10 Q99714 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12297990 0.90 MEN1 (0.58) ALOX5MEN1KMT2ANPC1RAB9A
SCHEMBL12297663 0.89 MEN1 (0.66) ALOX5MEN1KMT2ANPC1RAB9A
SCHEMBL12298201 0.87 NPC1 (0.52) ALOX5MEN1KMT2ANPC1RAB9A
SCHEMBL12297746 0.86 MEN1 (0.60) ALOX5MEN1KMT2ANPC1RAB9A
SCHEMBL6159226 0.86 MEN1 (0.59) ALOX5MEN1KMT2ANPC1RAB9A
SCHEMBL7040080 0.84 MEN1 (0.69) ALOX5MEN1KMT2ANPC1RAB9A
SCHEMBL12297322 0.82 ALOX5 (0.67) ALOX5MEN1KMT2ANPC1RAB9A
SCHEMBL12298062 0.82 MEN1 (0.67) ALOX5MEN1KMT2ANPC1RAB9A
SCHEMBL12298190 0.82 PSEN1 (0.53) ALOX5MEN1KMT2ANPC1RAB9A
SCHEMBL12298275 0.81 MAPT (0.72) ALOX5MEN1KMT2ANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8017629-B2 Compounds and uses thereof in modulating amyloid β NEUROGENETIC PHARMACEUTICALS, INC. (US) 2011-09-13 — — US disclosed
US-8017629-B2 Compounds and uses thereof in modulating amyloid β NEUROGENETIC PHARMACEUTICALS, INC. (US) 2011-09-13 — — US disclosed
US-20100324032-A1 COMPOUNDS AND USES THEREOF IN MODULATING AMYLOID BETA NEUROGENETIC PHARMACEUTICALS, INC. 2010-12-23 — — US disclosed
US-20100324032-A1 COMPOUNDS AND USES THEREOF IN MODULATING AMYLOID BETA NEUROGENETIC PHARMACEUTICALS, INC. 2010-12-23 — — US disclosed
US-7781442-B2 Compounds and uses thereof in modulating amyloid beta NEUROGENETIC PHARMACEUTICALS, INC. (US) 2010-08-24 — — US disclosed
US-7781442-B2 Compounds and uses thereof in modulating amyloid beta NEUROGENETIC PHARMACEUTICALS, INC. (US) 2010-08-24 — — US disclosed
US-20070260058-A1 Compounds and Uses Thereof in Modulating Amyloid Beta TORREYPINES THERAPEUTICS INC. 2007-11-08 — — US disclosed
US-20070260058-A1 Compounds and Uses Thereof in Modulating Amyloid Beta TORREYPINES THERAPEUTICS INC. 2007-11-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100324032-A1 COMPOUNDS AND USES THEREOF IN MODULATING AMYLOID BETA APP, BACE1, BACE2 ALOX5 1213/4885MEN1 2959/4885KMT2A 3770/4885
US-20070260058-A1 Compounds and Uses Thereof in Modulating Amyloid Beta APP, BACE1, BACE2 ALOX5 1213/4885MEN1 2959/4885KMT2A 3770/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback